Showing results (231-240 of 253) with videos related to

Sort By:
Pageof 26
Science Immunology|April 19, 2024
TIM-3+ CD8 T cells with a terminally exhausted phenotype retain functional capacity in hematological malignanciesSimone A Minnie, Olivia G Waltner, Ping Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 28, 2024
Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial MalignanciesCarla A Jaeger-Ruckstuhl, Jennifer M Specht, Jenna M Voutsinas, et al.
Oncoimmunology|July 30, 2016
CMRF-56(+) blood dendritic cells loaded with mRNA induce effective antigen-specific cytotoxic T-lymphocyte responsesPhillip D Fromm, Michael S Papadimitrious, Jennifer L Hsu, et al.
Transplantation and Cellular Therapy|April 9, 2023
Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell TherapyNicolas Gazeau, Emily C Liang, Qian Vicky Wu, et al.
Molecular Cancer Therapeutics|April 11, 2022
B7-H3 Specific CAR T Cells for the Naturally Occurring, Spontaneous Canine Sarcoma ModelShihong Zhang, R Graeme Black, Karan Kohli, et al.
Blood|April 28, 2016
Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHLXiuli Wang, Leslie L Popplewell, Jamie R Wagner, et al.
Cancer|May 3, 2017
T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomasSeth M Pollack, Qianchuan He, Jennifer H Yearley, et al.
Nature|January 11, 2019
De novo design of potent and selective mimics of IL-2 and IL-15Daniel-Adriano Silva, Shawn Yu, Umut Y Ulge, et al.
Blood Advances|July 24, 2025
Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysisNausheen Ahmed, Swetha Thiruvengadam, Mehdi Hamadani, et al.
Journal for Immunotherapy of Cancer|December 18, 2020
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse eventsMarcela V Maus, Sara Alexander, Michael R Bishop, et al.
Pageof 26